Skip to main content
. 2024 Nov 11;14:27550. doi: 10.1038/s41598-024-59186-1

Table 4.

Most common, all-causality, non-hematologic TEAEs (in > 20% of patients).

TEAE, n (%) Isa (N = 21)
All grades Grade ≥ 3
Infusion reaction 13 (61.9) 0
Upper respiratory infection 9 (42.9) 3 (14.3)
Decreased weight 6 (28.6) 1 (4.8)
Pneumonia 6 (28.6) 4 (19.0)
Bone pain 5 (23.8) 2 (9.5)
Constipation 5 (23.8) 0
Diarrhea 5 (23.8) 0

Isa, isatuximab; TEAE, treatment-emergent adverse event.